首页 产品中心
  • NU 7026
  • 2-(4-吗啉基)-4H-萘并[1,2-B]吡喃-4-酮;DNA-PK Inhibitor II;LY293646; NU7026; NU-7026; LY 293646; LY-293646
  • 货号: abs810645
    CAS号: 154447-35-5
    分子式: C17H15NO3
    分子量: 281.31
    产品说明书
    分享:
    货号-规格 货期 价格 数量
    abs810645-5mg 1-2周 ¥575.00
    - +
    abs810645-10mg 1-2周 ¥899.00
    - +
    abs810645-50mg 1-2周 ¥3290.00
    - +
    abs810645-100mg 1-2周 ¥5921.00
    - +
    大包装询价
    产品描述
    描述

    NU 7026 is a potent DNA-PK inhibitor with IC50 of 0.23 μM, 60-fold selective for DNA-PK than PI3K and inactive against both ATM and ATR.

    纯度
    >98%
    储存/保存方法
    store at -20℃ for one year(Powder);
    in DMSO or others solvent store at 2-4℃ for two weeks, at -80℃ for six months.
    基本信息
    别名
    2-(4-吗啉基)-4H-萘并[1,2-B]吡喃-4-酮;DNA-PK Inhibitor II;LY293646; NU7026; NU-7026; LY 293646; LY-293646
    外观
    Powder
    可溶性/溶解性
    DMSO :2.8 mg/mL (10 mM)





    生物活性
    靶点
    DNA-PK;PI3K
    In vitro(体外研究)
    NU7026 potentiates ionizing radiation induced cytotoxicity in a concentration-dependent manner in V3YAC and PARP-1+/+ cells. NU7026 completely abolishes potentially lethal damage recovery in growth-arrested cells. NU7026 inhibits DNA DSB repair by 56% in the V3YAC cell line. NU7026 (10 μM) potentiates the growth inhibitory effects of idarubicin, daunorubicin, doxorubicin, etoposide, mAMSA, and mitoxantrone with PF50 values ranging from approximately 19 for mAMSA to approximately 2 for idarubicin in K562 cells. NU7026 (10 μM) also potentiates the growth inhibitory effect of etoposide in this leukemia cell line with a PF50 value of 10.53. NU7026 (10 μM) enhances the etoposide-induced cell cycle G2 blockade in K562 cells. NU7026 potentiates topo II poisons involves inhibition of nonhomologous end joining and a G2/M checkpoint arrest. NU7026 (10 μM) exposure of 4 h in combination with 3 Gy radiation is required for a significant radiosensitisation effect in CH1 human ovarian cancer cells. NU7026 ( NU7026 (55 μM) results in a dramatic induction of telomere fusion in p53 null MEFs and significantly fewer telomere fusions in p53 and ligase IV double null MEFs.
    In vivo(体内研究)
    NU7026 (20mg/kg, i.v.) undergoes rapid plasma clearance (0.108/hour) in mice and this is largely attributed to extensive metabolism. Bioavailability following interperitoneal (i.p.) and p.o. administration of NU7026 at dose of 20 mg/kg is 20 and 15%, respectively.
    温馨提示:本产品仅作科研实验使用,不支持临床等研究
        提示: 尊敬的客户您好,如果您对我们的产品有什么疑问或想要了解的,可以点击“我要提问”按钮填写您的疑问。
        提交不成功?请联系info@absin.cn。
        我要提问

    促销资讯 更多

      订购信息
      您可以从我们的授权经销商处购买absin产品或获得技术支持。若要查看您所在地区的经销商,请从以下的下拉列表中选择。
      GO
      • 0